Brainstorm Cell Therapeutics Files 8-K
Ticker: BCLI · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update, financials
TL;DR
Brainstorm Cell Therapeutics filed an 8-K on 4/21/25 covering corporate changes and financials.
AI Summary
Brainstorm Cell Therapeutics Inc. filed an 8-K on April 21, 2025, reporting on events as of April 20, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws, shareholder nominations pursuant to Exchange Act Rule 14a-11, and financial statements and exhibits. The company, incorporated in Delaware, operates in the Biological Products sector.
Why It Matters
This 8-K filing signals potential corporate governance changes and the submission of important financial and operational updates for Brainstorm Cell Therapeutics Inc.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting corporate actions and financial updates, not indicating immediate financial distress or significant negative events.
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- April 20, 2025 (date) — Earliest event reported date
- April 21, 2025 (date) — Filing date
FAQ
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text.
Who are the individuals nominated by shareholders under Exchange Act Rule 14a-11?
The filing mentions shareholder nominations pursuant to Exchange Act Rule 14a-11, but the names of the nominees are not specified in the provided text.
What are the key financial highlights or figures reported in the financial statements?
The filing states that financial statements and exhibits are included, but the specific financial figures are not detailed in the provided text.
What is the primary business of Brainstorm Cell Therapeutics Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code, Brainstorm Cell Therapeutics Inc. is in the business of Biological Products (NO DIAGNOSTIC SUBSTANCES).
When was the company incorporated and what is its fiscal year end?
The company was incorporated in Delaware and its fiscal year ends on December 31st.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).